A Randomized Double-blind, Placebo-controlled, Cross-over Trial of Ganaxolone in Children and Adolescents with Fragile X Syndrome (S46.005)

Conclusions:Ganaxolone was generally safe and well tolerated in children with FXS and showed improvements in anxiety, hyperactivity and attention in a subset of patients with baseline anxiety.Study Supported by:U.S. Army Medical Research and Material Command (USAMRMC) FUNDING MECHANISM: Contract # W81XWH-11-1-0626Jérôme Lejeune foundation, Marguerite Marie Delacroix foundation, FRAXA Research FoundationDisclosure: Dr. Tsai has received personal compensation for activities with Marinus. Dr. Tsai has received research support from Marinus. Dr. Ligsay has nothing to disclose. Dr. Van Dijck has nothing to disclose. Dr. Kooy has received personal compensation for activities with Marinus as a scientific advisory board member. Dr. Hessl has received personal compensation for activities with Marinus. Dr. Bickel has nothing to disclose. Dr. Hagerman has received personal compensation for activities with Novartis, Roche Diagnostics Corporation, Zynerba, Ovid, and Marinus as a consultant. Dr. Patroneva has received personal compensation for activities with Marinus as the Chief Medical Officer and holds stock options with Marinus.
Source: Neurology - Category: Neurology Authors: Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research